Abilita Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 4

Abilita Therapeutics General Information

Description

Developer of oncological drugs designed to target membrane proteins. The company leverages technology-directed evolution to identify target variants (EMPs) that can overcome the challenges, yet maintain the relevant protein structure, enabling clinicians to have access to tool receptors for antibody discovery and technical service through the generation of enabled membrane proteins.

Contact Information

Website
abilitatx.com
Formerly Known As
Abilita Bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5785 Oberlin Drive
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 5785 Oberlin Drive
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858)

Abilita Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Abilita Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator Completed Pre-Clinical Trials
5. Seed Round 21-Feb-2023 Completed Pre-Clinical Trials
4. Grant 15-Sep-2021 Completed Product Development
3. Grant 20-Sep-2016 Completed Product Development
2. Accelerator/Incubator 01-Jan-2015 Completed Product Development
1. Angel (individual) 01-Jan-2015 Completed Product Development
To view Abilita Therapeutics’s complete valuation and funding history, request access »

Abilita Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed-3
Seed-2
Seed-1 177,788 $0.000010 8% $1.49 $1.49 1x $1.49 2.29%
Seed 2,114,462 $0.000010 8% $3.55 $3.55 1x $3.55 19.76%
To view Abilita Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Abilita Therapeutics Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Abilita Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250092146-A1 Anti-ccr8 antibodies, conjugates, and uses thereof Pending 28-Apr-2023
US-10845367-B2 Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents Active 04-May-2016
US-20190137496-A1 Methods and platform for preparing multispanning membrane proteins Active 04-May-2016
EP-3452516-A1 Methods and platform for preparing multispanning membrane proteins Pending 04-May-2016
EP-3452516-A4 Methods and platform for preparing multispanning membrane proteins Pending 04-May-2016 G01N33/577
To view Abilita Therapeutics’s complete patent history, request access »

Abilita Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Abilita Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Two Bear Capital Venture Capital Minority
U.S. Department of Health and Human Services Government
Johnson & Johnson Innovation - JLABS Accelerator/Incubator
CONNECT(San Diego) Accelerator/Incubator
To view Abilita Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Abilita Therapeutics FAQs

  • When was Abilita Therapeutics founded?

    Abilita Therapeutics was founded in 2014.

  • Where is Abilita Therapeutics headquartered?

    Abilita Therapeutics is headquartered in San Diego, CA.

  • What is the size of Abilita Therapeutics?

    Abilita Therapeutics has 13 total employees.

  • What industry is Abilita Therapeutics in?

    Abilita Therapeutics’s primary industry is Drug Discovery.

  • Is Abilita Therapeutics a private or public company?

    Abilita Therapeutics is a Private company.

  • What is Abilita Therapeutics’s current revenue?

    The current revenue for Abilita Therapeutics is .

  • How much funding has Abilita Therapeutics raised over time?

    Abilita Therapeutics has raised $7.5M.

  • Who are Abilita Therapeutics’s investors?

    Two Bear Capital, U.S. Department of Health and Human Services, Johnson & Johnson Innovation - JLABS, and CONNECT(San Diego) have invested in Abilita Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »